Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1361690rdf:typepubmed:Citationlld:pubmed
pubmed-article:1361690lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:1361690lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:1361690lifeskim:mentionsumls-concept:C0013030lld:lifeskim
pubmed-article:1361690lifeskim:mentionsumls-concept:C0600688lld:lifeskim
pubmed-article:1361690lifeskim:mentionsumls-concept:C0678723lld:lifeskim
pubmed-article:1361690lifeskim:mentionsumls-concept:C0445223lld:lifeskim
pubmed-article:1361690lifeskim:mentionsumls-concept:C1552599lld:lifeskim
pubmed-article:1361690lifeskim:mentionsumls-concept:C0205549lld:lifeskim
pubmed-article:1361690lifeskim:mentionsumls-concept:C1704787lld:lifeskim
pubmed-article:1361690lifeskim:mentionsumls-concept:C0920591lld:lifeskim
pubmed-article:1361690lifeskim:mentionsumls-concept:C0205556lld:lifeskim
pubmed-article:1361690lifeskim:mentionsumls-concept:C0458003lld:lifeskim
pubmed-article:1361690pubmed:issue3lld:pubmed
pubmed-article:1361690pubmed:dateCreated1993-1-26lld:pubmed
pubmed-article:1361690pubmed:abstractTextA qualitative assessment of developmental toxicity within a series of 12 structurally related compounds, 11 of which were active dopamine mimetics and one was inactive, was conducted in rats treated orally by gavage during the major period of organogenesis. Doses were chosen where possible to be equipotent in terms of pharmacological activity. The series was typified by the compound BRL 16644 (2-[[3,4-dihydro-2,2-dimethyl-4-[3-(trifluoromethyl)phenyl]- 2H-1-benzopyran-7-yl]oxy]-N,N-dimethyl-ethanamine: Chemical Abstracts No. 59257-24-8). Five of these compounds were clearly teratogenic producing specific abnormalities typified by anasarca, brachygnathia and cleft palate. Similar levels of maternal toxicity, particularly stereotypic behaviour, and foetotoxicity were seen in both teratogenic and non-teratogenic compounds suggesting that neither maternal nor foetotoxicity plays a role in the aetiology of the abnormalities. Four of the teratogenic compounds contained a trifluoromethyl group in the 4-phenyl ring and, within this series of compounds, substitution with this group appears to confer teratogenicity. Although equipotent doses were used this only pertained to the adult and as only limited pharmacokinetic data were available, including the extent of placental transfer, the influence of this group is not clear. Investigations have been undertaken to relate the teratogenic potential of these compounds to a number of their chemical descriptors, including electronic, steric, quantum chemical and hydrophobicity parameters, to try and clarify the influence of the trifluoromethyl group.lld:pubmed
pubmed-article:1361690pubmed:languageenglld:pubmed
pubmed-article:1361690pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1361690pubmed:citationSubsetIMlld:pubmed
pubmed-article:1361690pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1361690pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1361690pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1361690pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1361690pubmed:statusMEDLINElld:pubmed
pubmed-article:1361690pubmed:monthDeclld:pubmed
pubmed-article:1361690pubmed:issn0300-483Xlld:pubmed
pubmed-article:1361690pubmed:authorpubmed-author:BaldwinJ AJAlld:pubmed
pubmed-article:1361690pubmed:authorpubmed-author:RidingsJ EJElld:pubmed
pubmed-article:1361690pubmed:issnTypePrintlld:pubmed
pubmed-article:1361690pubmed:day4lld:pubmed
pubmed-article:1361690pubmed:volume76lld:pubmed
pubmed-article:1361690pubmed:ownerNLMlld:pubmed
pubmed-article:1361690pubmed:authorsCompleteYlld:pubmed
pubmed-article:1361690pubmed:pagination197-207lld:pubmed
pubmed-article:1361690pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:1361690pubmed:meshHeadingpubmed-meshheading:1361690-...lld:pubmed
pubmed-article:1361690pubmed:meshHeadingpubmed-meshheading:1361690-...lld:pubmed
pubmed-article:1361690pubmed:meshHeadingpubmed-meshheading:1361690-...lld:pubmed
pubmed-article:1361690pubmed:meshHeadingpubmed-meshheading:1361690-...lld:pubmed
pubmed-article:1361690pubmed:meshHeadingpubmed-meshheading:1361690-...lld:pubmed
pubmed-article:1361690pubmed:meshHeadingpubmed-meshheading:1361690-...lld:pubmed
pubmed-article:1361690pubmed:meshHeadingpubmed-meshheading:1361690-...lld:pubmed
pubmed-article:1361690pubmed:meshHeadingpubmed-meshheading:1361690-...lld:pubmed
pubmed-article:1361690pubmed:meshHeadingpubmed-meshheading:1361690-...lld:pubmed
pubmed-article:1361690pubmed:meshHeadingpubmed-meshheading:1361690-...lld:pubmed
pubmed-article:1361690pubmed:meshHeadingpubmed-meshheading:1361690-...lld:pubmed
pubmed-article:1361690pubmed:meshHeadingpubmed-meshheading:1361690-...lld:pubmed
pubmed-article:1361690pubmed:year1992lld:pubmed
pubmed-article:1361690pubmed:articleTitleA qualitative assessment of developmental toxicity within a series of structurally related dopamine mimetics.lld:pubmed
pubmed-article:1361690pubmed:affiliationSmithKline Beecham Pharmaceuticals, Welwyn, Herts, UK.lld:pubmed
pubmed-article:1361690pubmed:publicationTypeJournal Articlelld:pubmed